Clinical study on 3D-CRT combined with nimotuzumab and chemotherapy in the treatment of stages Ⅲ-ⅣA nasopharyngeal carcinoma
10.3760/cma.j.issn.1008-6706.2012.09.006
- VernacularTitle:尼妥珠单抗联合放化疗治疗Ⅲ、ⅣA期鼻咽癌的临床研究
- Author:
Wubing TANG
;
Wen YANG
;
Yang CAO
;
Churong WU
;
Xingxi PAN
;
Zhenheng LIU
;
Yongsheng ZHANG
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms;
Radiotherapy conformal;
Chemotherapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(9):1293-1295
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and safety of three-dimensional conformal radiotherapy (3D-CRT) m combination with nimotuzumab and chemotherapy in treatment patients with locoregionally advanced nasopharyngeal carcinoma.Methods 60 patients with stages Ⅲ-ⅣA nasopharyngeal carcinoma were enrolled.All patients were treated with 3D-CRT and concurrent and sequential chemotherapy by paclitaxel and eisplatin and given nimotuzumab 100mg i.v.weekly for 6 ～ 7 weeks before radiotherapy.Results After two months,the complete response rates(CR) of nasopharyngeal carcinoma and cervix lymph nodes were 98.3％,96.7％ respectively,l-year locoregional control and distant metastasis-free survival rates were 100％,96.7％ in 38 patients.2-year,3-year locoregional control and distant metastasis-free survival rates were 100％ in 16 patients and 8 patients.The major side effects included oral mucositis,actinodermatitis,neutropenia,nausea,vomiting,and fatigue.Grade 3 acute oral mucositis often occured.No skin rash or allergic toxicities appeared.All the effects were tolerable.Conclusion 3D-CRT combined with nimotuzumab and peclitaxel and cisplatin chemotherapy may improve the complete response rate and locoregional control and distant metastasis-free survival rate on locoregionally advanced nasopharyngeal carcinoma,with mild to moderate side effects.
